Coloplast Slashes Forecast, Writes Down Kerecis by DKK 3B

HUMLEBAEK, Denmark – April 23, 2026 – Danish medical device giant Coloplast A/S delivered a shock to the market today, announcing a significant downward revision of its financial guidance for the 2025/26 fiscal year and a DKK 3.0 billion impairment loss on its Kerecis acquisition. The drastic measures are a direct result of a slower-than-expected market recovery in the U.S. outpatient wound care sector, crippled by sweeping Medicare reimbursement policy changes that have decimated the growth outlook for its once-promising Kerecis skin substitute business.

The news underscores the profound impact of regulatory shifts on the medical technology industry, turning a key growth driver for Coloplast into a significant financial drag and raising questions about the high-stakes world of MedTech acquisitions.

A Financial Hit from Policy Shockwaves

Coloplast's revised forecast paints a stark picture of the fallout. The company now expects group-wide organic growth to be 5-6% for the fiscal year, a notable reduction from the previously anticipated figure of around 7%. The outlook for EBIT growth in constant currencies was similarly trimmed, now projected at approximately 5%, down from 7%.

The epicenter of this financial earthquake is Kerecis, the Icelandic fish-skin wound care company Coloplast acquired in a high-profile deal. Once expected to be a significant growth engine, Kerecis is now projected to deliver around 0% organic growth for the fiscal year—a dramatic collapse from the previously adjusted forecast of 10% and an initial expectation of 25%. Its EBIT margin is also expected to fall to around 0%, a far cry from the double-digit figures anticipated earlier.

This performance collapse forced the company to take a DKK 3.0 billion impairment loss against Kerecis's goodwill, effectively writing down nearly a third of its value on the books. The write-down, which will be logged as a special item, reduces the carrying book value of Kerecis from around DKK 9 billion to DKK 6 billion. While the accounting move has no immediate cash flow impact, it serves as a sobering admission that the sales disruption is more severe and prolonged than first thought.

Adding to the pressure, the company also noted increased negative impact from currency fluctuations, particularly the Hungarian forint, which is expected to shave around 80 basis points off the reported EBIT margin.

The Medicare Reimbursement Overhaul

The turmoil at Kerecis is not a story of product failure but of a seismic shift in the U.S. healthcare payment landscape. The U.S. Centers for Medicare & Medicaid Services (CMS) implemented a fundamental overhaul of how it pays for skin substitutes in the outpatient setting, which went into effect at the start of 2026.

For years, many of these advanced wound care products were reimbursed under an Average Sales Price (ASP) plus a percentage markup, a system that incentivized the use of higher-cost products. However, citing an explosion in Medicare Part B spending on these items—from roughly $250 million in 2019 to over $10 billion by 2024—CMS took decisive action. The agency reclassified most skin substitutes, including products like those from Kerecis, as "incident-to supplies."

This change eliminated the lucrative ASP-based payment model. Instead, these products are now paid at a standardized flat rate, which was set at just over $127 per square centimeter for 2026. For many manufacturers whose business models were built around the previous reimbursement structure, the change represented a massive and sudden drop in revenue per procedure. CMS's stated goal was to curb what it saw as abusive pricing and overutilization, projecting the move would slash spending by nearly 90% in 2026 alone.

For Coloplast, the slower-than-anticipated recovery suggests that outpatient clinics are struggling to adapt to this new economic reality, leading to a significant disruption in sales for Kerecis products in that specific but crucial market segment. While the company noted that growth in the inpatient hospital setting remained at a healthy double-digit level, it was not enough to offset the collapse in the outpatient channel.

Core Business Resilience Amidst Acquisition Woes

While the Kerecis situation has dominated headlines, Coloplast's latest financial report also highlights the resilience of its diversified portfolio. The company's core legacy businesses delivered strong results, acting as a crucial buffer against the wound care challenges.

The Chronic Care division, which includes Ostomy Care and Continence Care, continued its solid performance. Ostomy Care grew 7% organically in the second quarter, buoyed by double-digit growth in the U.S. market. Continence Care and Voice & Respiratory Care both posted robust 8% organic growth.

Similarly, the Interventional Urology business continued its strong momentum with 8% growth, driven primarily by its Men's Health segment in the United States. This steady performance across multiple, well-established business areas demonstrates the strategic value of Coloplast's diversification, which has helped maintain overall group organic growth at a respectable 6% for the first half of the fiscal year.

This contrast throws the challenges of integrating a high-growth, specialized acquisition like Kerecis into sharp relief. While such deals offer the promise of rapid expansion into new, innovative markets, they also carry concentrated risks, particularly when a market's viability is so heavily dependent on specific regulatory and reimbursement frameworks.

A Test of Long-Term Strategy

The severe setback with Kerecis presents a significant test for Coloplast's long-term vision. Despite the immediate financial pain and the DKK 3.0 billion write-down, the company has publicly reaffirmed its commitment to its 'Impact4' five-year strategy, which extends to 2030.

This long-term ambition calls for an average organic revenue growth of 7-8% and an EBIT growth that outpaces revenue over the period. Hitting these targets has become significantly more challenging with a key intended growth driver now stalled. The situation forces a broader examination of the advanced wound care market, where the entire industry must now navigate the new payment landscape established by CMS.

For Coloplast, the path forward will involve stabilizing the Kerecis business under the new market conditions while continuing to lean on the steady strength of its chronic care and urology franchises. The company's ability to maintain its long-term growth ambitions will depend on whether the Kerecis disruption is a temporary, albeit severe, storm or a permanent impairment to a once-promising new frontier.